Recursion Pharmaceuticals Stock News

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) have been given an average rating of “Buy” by the seven ratings firms that are currently covering the stock, MarketBeat reports. Three analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month target price among analysts that […]

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)s stock price rose 5.9% during trading on Thursday . The company traded as high as $18.72 and last traded at $18.52. Approximately 10,500 shares traded hands during mid-day trading, a decline of 98% from the average daily volume of 665,035 shares. The stock had previously closed at $17.48. A number of []

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has been given a consensus rating of Buy by the seven brokerages that are presently covering the firm, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average twelve-month target price among analysts that have issued []

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) COO Tina Marriott Larson sold 2,500 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Thursday, November 18th. The shares were sold at an average price of $18.92, for a total transaction of $47,300.00. The sale was disclosed in a filing with the SEC, which is available at this []

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) shares were down 10.8% during mid-day trading on Monday after an insider sold shares in the company. The company traded as low as $17.68 and last traded at $17.68. Approximately 5,647 shares changed hands during trading, a decline of 99% from the average daily volume of 606,380 shares. The stock had []

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Dean Y. Li sold 13,474 shares of the stock in a transaction on Friday, November 19th. The shares were sold at an average price of $20.20, for a total value of $272,174.80. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Shares []

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Dean Y. Li sold 5,626 shares of the businesss stock in a transaction dated Wednesday, November 17th. The stock was sold at an average price of $20.04, for a total transaction of $112,745.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at []

Surface Oncology (NASDAQ:SURF) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability. Profitability This table compares Surface Oncology and Recursion Pharmaceuticals net margins, return on equity and return []

Price T Rowe Associates Inc. MD acquired a new stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 583,085 shares of the companys stock, valued at approximately $21,283,000. Several other large investors have also made changes to their positions in []

Investors reacted negatively to the company's Q3 update.

SALT LAKE CITY, Oct. 7, 2021 /PRNewswire/ -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, auto

SALT LAKE CITY--(BUSINESS WIRE)--BioHive, with a mission to brand, build and bring together Utah's robust and growing life sciences industry, names Katelin Roberts Executive Director.

SALT LAKE CITY, Sept. 29, 2021 /PRNewswire/ -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, a

SALT LAKE CITY, Aug. 13, 2021 /PRNewswire/ -- Recursion (Nasdaq: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, aut

SALT LAKE CITY, July 13, 2021 /PRNewswire/ -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, aut